Total
1
Shares
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) announces positive data from its phase one intravenous clinical trial for RECCE 327 (R327)
  • R327 is designed to treat serious bacterial infections including sepsis
  • In its first cohort of the phase one trial, nine healthy male subjects demonstrated R327’s safety and tolerability
  • An independent safety committee has now approved an increase in dosage from 50 milligrams to 150 milligrams in the second cohort
  • The study is on track to have all Phase I dosing complete by the second quarter of this year
  • Shares are trading 6.80 per cent higher today at $1.10 each

Recce Pharmaceuticals (RCE) has announced positive data from its phase one intravenous clinical trial for RECCE 327 (R327).

R327 is designed to treat serious bacterial infections including sepsis.

In its first cohort of the phase one trial, nine healthy male subjects demonstrated R327’s safety and tolerability. There were no clinically significant changes in vital signs, clinical, adverse events, or laboratory parameters associated with R327.

An independent safety committee has now approved an increase in dosage from 50 milligrams to 150 milligrams in the second cohort, with subjects expected to be dosed today at Adelaide’s CMAX clinical trial facility.

CEO James Graham said he is pleased with the results.

“R327 continues to make significant progress in the clinic, both in this Phase I intravenous trial and a parallel Phase I/II topical trial on patients with serious burn wound infections,” he said.

“We’re pleased to see R327 (50mg) tolerated as an intravenous infusion in Cohort One subjects.”

The study is on track to have all phase one dosing complete by the second quarter of this year.

Shares are trading 6.80 per cent higher today at $1.10 each at 11.24 pm AEDT.

RCE by the numbers
More From The Market Herald
Siren Gold (ASX:SNG) - Chairman, Brian Rodan

" Siren Gold (ASX:SNG) to begin scoping study at NZ gold projects

Siren Gold (ASX:SNG) will undertake a scoping study for underground development at its Big River and…

" Mad Paws (ASX:MPA) reports 199pc growth December-quarter revenue

Pet services marketplace Mad Paws (ASX:MPA) has reported operating revenue for the December quarter of $2…

" Vanadium Resources (ASX:VR8) increases stake in Steelpoortdrift Project

Vanadium Resources (A:VR8) increased its interest to 73.95 per cent in the Tier 1 Steelpoortdrift Vanadium…

" Stanmore (ASX:SMR) awards EPSA Pacific $564m open-cut mining contract

Stanmore Resources (ASX:SMR) has awarded EPSA Pacific a $564 million mining contract at its Isaac Downs…